414 related articles for article (PubMed ID: 31831267)
1. Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader.
Potjewyd F; Turner AW; Beri J; Rectenwald JM; Norris-Drouin JL; Cholensky SH; Margolis DM; Pearce KH; Herring LE; James LI
Cell Chem Biol; 2020 Jan; 27(1):47-56.e15. PubMed ID: 31831267
[TBL] [Abstract][Full Text] [Related]
2. EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex.
Hsu JH; Rasmusson T; Robinson J; Pachl F; Read J; Kawatkar S; O' Donovan DH; Bagal S; Code E; Rawlins P; Argyrou A; Tomlinson R; Gao N; Zhu X; Chiarparin E; Jacques K; Shen M; Woods H; Bednarski E; Wilson DM; Drew L; Castaldi MP; Fawell S; Bloecher A
Cell Chem Biol; 2020 Jan; 27(1):41-46.e17. PubMed ID: 31786184
[TBL] [Abstract][Full Text] [Related]
3. PROTAC Linkerology Leads to an Optimized Bivalent Chemical Degrader of Polycomb Repressive Complex 2 (PRC2) Components.
Bashore FM; Foley CA; Ong HW; Rectenwald JM; Hanley RP; Norris-Drouin JL; Cholensky SH; Mills CA; Pearce KH; Herring LE; Kireev D; Frye SV; James LI
ACS Chem Biol; 2023 Mar; 18(3):494-507. PubMed ID: 36877831
[TBL] [Abstract][Full Text] [Related]
4. Targeted Degradation of PRC1 Components, BMI1 and RING1B, via a Novel Protein Complex Degrader Strategy.
Park KS; Qin L; Kabir M; Luo K; Dale B; Zhong Y; Kim A; Wang GG; Kaniskan HÜ; Jin J
Adv Sci (Weinh); 2023 Apr; 10(10):e2205573. PubMed ID: 36737841
[TBL] [Abstract][Full Text] [Related]
5. Identification and Assessments of Novel and Potent Small-Molecule Inhibitors of EED-EZH2 Interaction of Polycomb Repressive Complex 2 by Computational Methods and Biological Evaluations.
Zhu K; Du D; Yang R; Tao H; Zhang H
Chem Pharm Bull (Tokyo); 2020 Jan; 68(1):58-63. PubMed ID: 31685780
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
7. Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction.
Du D; Xu D; Zhu L; Stazi G; Zwergel C; Liu Y; Luo Z; Li Y; Zhang Y; Zhu K; Ding Y; Liu J; Fan S; Zhao K; Zhang N; Kong X; Jiang H; Chen K; Zhao K; Valente S; Min J; Duan W; Luo C
J Med Chem; 2021 Jun; 64(12):8194-8207. PubMed ID: 34077206
[TBL] [Abstract][Full Text] [Related]
8. Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase.
Bagal SK; Gregson C; O' Donovan DH; Pike KG; Bloecher A; Barton P; Borodovsky A; Code E; Fillery SM; Hsu JH; Kawatkar SP; Li C; Longmire D; Nai Y; Nash SC; Pike A; Robinson J; Read JA; Rawlins PB; Shen M; Tang J; Wang P; Woods H; Williamson B
J Med Chem; 2021 Dec; 64(23):17146-17183. PubMed ID: 34807608
[TBL] [Abstract][Full Text] [Related]
9. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
Zhao Y; Guan YY; Zhao F; Yu T; Zhang SJ; Zhang YZ; Duan YC; Zhou XL
Eur J Med Chem; 2022 Mar; 231():114144. PubMed ID: 35093670
[TBL] [Abstract][Full Text] [Related]
10. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.
Qi W; Zhao K; Gu J; Huang Y; Wang Y; Zhang H; Zhang M; Zhang J; Yu Z; Li L; Teng L; Chuai S; Zhang C; Zhao M; Chan H; Chen Z; Fang D; Fei Q; Feng L; Feng L; Gao Y; Ge H; Ge X; Li G; Lingel A; Lin Y; Liu Y; Luo F; Shi M; Wang L; Wang Z; Yu Y; Zeng J; Zeng C; Zhang L; Zhang Q; Zhou S; Oyang C; Atadja P; Li E
Nat Chem Biol; 2017 Apr; 13(4):381-388. PubMed ID: 28135235
[TBL] [Abstract][Full Text] [Related]
11. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
[TBL] [Abstract][Full Text] [Related]
12. Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2.
Dale B; Anderson C; Park KS; Kaniskan HÜ; Ma A; Shen Y; Zhang C; Xie L; Chen X; Yu X; Jin J
ACS Pharmacol Transl Sci; 2022 Jul; 5(7):491-507. PubMed ID: 35837138
[TBL] [Abstract][Full Text] [Related]
13. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns.
Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW
Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
[TBL] [Abstract][Full Text] [Related]
15. Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.
Chen H; Gao S; Li J; Liu D; Sheng C; Yao C; Jiang W; Wu J; Chen S; Huang W
Oncotarget; 2015 May; 6(15):13049-59. PubMed ID: 25944687
[TBL] [Abstract][Full Text] [Related]
16. Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment.
Cook N; Chen J; Zhou J; Wu D
Curr Top Med Chem; 2021; 21(31):2771-2777. PubMed ID: 34544341
[TBL] [Abstract][Full Text] [Related]
17. Mutations in genes encoding polycomb repressive complex 2 subunits cause Weaver syndrome.
Imagawa E; Higashimoto K; Sakai Y; Numakura C; Okamoto N; Matsunaga S; Ryo A; Sato Y; Sanefuji M; Ihara K; Takada Y; Nishimura G; Saitsu H; Mizuguchi T; Miyatake S; Nakashima M; Miyake N; Soejima H; Matsumoto N
Hum Mutat; 2017 Jun; 38(6):637-648. PubMed ID: 28229514
[TBL] [Abstract][Full Text] [Related]
18. Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED Binders.
Tomassi S; Romanelli A; Zwergel C; Valente S; Mai A
J Med Chem; 2021 Aug; 64(16):11774-11797. PubMed ID: 34351144
[TBL] [Abstract][Full Text] [Related]
19. Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer.
Martin MC; Zeng G; Yu J; Schiltz GE
J Med Chem; 2020 Dec; 63(24):15344-15370. PubMed ID: 33283516
[TBL] [Abstract][Full Text] [Related]
20. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer.
Kim W; Bird GH; Neff T; Guo G; Kerenyi MA; Walensky LD; Orkin SH
Nat Chem Biol; 2013 Oct; 9(10):643-50. PubMed ID: 23974116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
